Compare New York Times Co (NYT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Travere Therapeutics Inc. Common Stock — how do they compare? New York Times Co trades at $67.13 (market cap $10.83B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: New York Times Co is far larger — about 2.2× Travere Therapeutics Inc. Common Stock's market cap, and New York Times Co pays a 1.37% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 82 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NYT | TVTX | |
|---|---|---|
Market Cap | $10.83B | $5.02B |
Volume | 1,004,378 | 2,060,842 |
Sector | Media | Health |
52-Week High | $85.86 | $67.52 |
52-Week Low | $54.86 | $26.79 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $10.22B | $5.15B |
Dividend Yield | 1.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.88, up 1.21% today, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82B in 2025 with a net income margin of 12.17%, and the company has beaten EPS estimates for three consecutive quarters. A recent shareholder lawsuit alleging bias in reporting and the ongoing AI copyright case with OpenAI are key news items.
The outlook is mixed: solid earnings growth and a consensus price target of $81.50 suggest upside, but legal risks and a bearish technical picture near-term pose challenges. The stock offers a dividend yield supported by positive cash flow, yet investor sentiment is cautious amid litigation concerns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
